Cancer Treatment Today

FERRIPROX® (deferiprone) is an iron chelator indicated for the treatment of patients with  iron overload form transfusions due to thalassemia syndromes when current chelation therapy, most commonly Exjade,  is inadequate. The approval in second line is reasonable both because the studies for approval were done in second line and because Ferroprox may be inferior to Exjade in first line (Cemak et al). This is not an innocuous drug; the most serious

FERRIPROX® (deferiprone) is an iron chelator indicated for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate. The approval in second line is reasonable both because the studies for approval were done in second line and because Ferroprox may be inferior to Exjade in first line (Cemak et al). This is not an innocuous drug; the most serious side effect seen in about

Standard guidelines recommend prophylactic Neulasta or Neupogen for patients who are treated with chemotherapy regimens that produce a greater than 20% risk of febrile neutropenia. These guidelines do not apply to the elderly. Elderly patients are at a higher risk of febrile neutropenia following chemotherapy, with worse morbidity and mortality rates. However, good prospective trial data are lacking with respect to elderly cancer patients due to

Ductal carcinoma in situ (DCIS) is a non-invasive breast cancer. In DCIS, abnormal cells are contained in the milk ducts. It is called “in situ” (which means "in place") because the cells have not left the milk ducts to invade nearby breast tissue. DCIS is also be intraductal (within the milk ducts) carcinoma, when it is larger but still not invasice. Without treatment, the abnormal cells could turn into invasive cancer over time. Some physicians

Fungal infections in the setting of stem cell transplant ind GVHD are notoriously hard to treat.SOmetimes, infections do nto respond. In some such situations, clinicians empirically combine more than one anti-fungal agents, such as amphotericin and micofungin. In vitro and mouse studies suggest greater efficacy for amphotericin and micofungin combination and favorable distributions, although human studies thus far have focused on comparative efficacies

Traditionally, the field of oncology was interested in complete partial response and progression. Later stable disease came into use, a measure of chemotherapy success that combined tumor shrinkage and cases in which there had been no change. Any growth , usually greater than a 25% increase in tumor size was called progression. Mixed response refers to a situation in which some metastases are responding and others are growing and/or new metastases

Guillain-Barr syndrome is a disorder in which the body's immune system attacks part of the peripheral nervous system. The onset can be very rapid or take few days to few weeks. Symptoms are weakness or tingling sensations in the legs. Sometimes, the weakness and abnormal sensations spread to the arms and upper body and progress to paralysis. There is no known cure for Guillain-Barr syndrome, but therapies can lessen the severity of the illness and